TZ30

Tirzepatide is a synthetic peptide that functions as a dual agonist for both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This unique mechanism of action distinguishes it from single-receptor agonists, offering enhanced efficacy in modulating glucose metabolism and promoting weight loss. Research applications for Tirzepatide primarily focus on its potential in studying metabolic disorders, including type 2 diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). Scientists utilize Tirzepatide to investigate pancreatic beta-cell function, insulin sensitivity, gastric emptying, and appetite regulation, providing valuable insights into novel therapeutic strategies. For optimal research integrity, Tirzepatide should be handled with care in a controlled laboratory environment. Researchers should wear appropriate personal protective equipment (PPE), including gloves and eye protection, to prevent direct contact. Avoid inhalation of powder or aerosols. Solutions should be prepared using sterile techniques and appropriate solvents as determined by specific experimental protocols. Consult the Safety Data Sheet (SDS) for comprehensive handling instructions. Proper storage is critical to maintain the stability and purity of Tirzepatide. The compound should be stored lyophilized at -20°C or below, protected from light and moisture. Once reconstituted, solutions should be used promptly or stored refrigerated (2-8°C) for short periods, typically no longer than 24-48 hours, depending on the solvent and concentration. Repeated freeze-thaw cycles should be avoided to prevent degradation. Always ensure containers are tightly sealed to prevent contamination and degradation.